Pomalidomide has multiple mechanisms of action, including immune regulation, anti angiogenesis, and anti-tumor effects.

1. Drug name

Common name: Pomalidomide

Product Name: POMALYST ®

2. Indications

Main indications: Used for the treatment of multiple myeloma patients who have received at least two previous therapies (including lenalidomide and bortezomib) and have disease progression. Approval is based on remission rate, and clinical survival benefits have not been validated.

3. Specifications and characteristics

Capsule specifications: 2mg, 4mg.

Characteristic: Difficult to dissolve in water and organic solvents.

4. Main components

Active ingredient: Pomalidomide (chemical name: (RS) -4-amino-2- (2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione).

Accessories: mannitol, pre gelatinized starch, sodium stearate fumarate, etc.

5. Usage and dosage

Standard dose: 4mg once daily, orally (21 day/28 day cycle), until disease progression. Dexamethasone can be used in combination.

Medication time: Fasting (2 hours before or after meals).

6. Dose adjustment

Blood toxicity:

Neutropenia: paused when ANC<500/mL, reduced to 3mg after recovery; repeated occurrence requires interruption.

Thrombocytopenia: Pause when<25000/mcL, reduce after recovery.

7. Medication precautions

Diet: Avoid taking with food.

Omission: If the missed dose is ≤ 12 hours, it can be supplemented, otherwise the daily dose will be skipped.

Vomiting: If vomiting occurs, there is no need to take additional medication, continue with the original plan.

8. Medication for special populations

Pregnant women: Prohibited (teratogenic risk), two types of contraception should be used.

Breastfeeding period: Medication or breastfeeding should be stopped.

Liver/kidney dysfunction: Avoid use for severe liver damage or creatinine levels>3.0mg/dL.

9. Adverse reactions

Common reactions (≥ 30%): fatigue, neutropenia, anemia, constipation, nausea, difficulty breathing, back pain, fever.

Serious reactions: Venous thromboembolism (3%), acute leukemia (rare).

10. Contraindications

Absolute taboos: pregnancy, allergies to ingredients.

11. Drug interactions

CYP3A4 inducers (such as rifampicin): should be avoided in combination as they may reduce efficacy.

Anticoagulants: increase the risk of bleeding and require monitoring.

12. Storage method

Temperature: 20-25 ° C (short-term 15-30 ° C allowed).

Protection: Avoid contact with powder and wear gloves when operating.

Pomalidomideinformation